Status:
COMPLETED
Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
Lead Sponsor:
Murdoch Childrens Research Institute
Collaborating Sponsors:
Monash University
University of Sydney
Conditions:
Intellectual Disability
Child Behavior Problem
Eligibility:
All Genders
6-18 years
Phase:
PHASE2
Brief Summary
This is a multi-site, double-blind, parallel group, randomized, placebo-controlled study of 140 participants comparing oral purified cannabidiol isolate (CBD) with placebo in reducing Severe Behaviora...
Eligibility Criteria
Inclusion
- Males and females aged 6 - 18 years of age;
- DSM-5 diagnosis of intellectual disability (ID):
- Full scale IQ \< 70 on standardized cognitive assessment. Testing results must be sighted by the investigators and performed within two years of enrollment. In the event that records of prior testing are unavailable or the assessment was more than 2 years prior, IQ will be estimated using the Wechsler Abbreviated Scale of Intelligence-II.
- Deficit in adaptive function (basis for severity rating of ID in DSM-5) in at least one activity of life on the Vineland Adaptive Behavior Scales (derives scores in Communication, Daily Living Skills and Socialization domains, and a Global Adaptive score). If records of prior testing are unavailable or the assessment was more than 2 years prior, this will be completed by the parent or guardian.
- SBP: Defined as scores of:
- 18 or higher on the Aberrant Behavior Checklist-Irritability subscale (ABC-I), and
- moderate or higher on the Clinical Global Impressions-Severity scale;
- No changes in either medication or other interventions in the 4 weeks prior to randomization, and intention to remain on same dose for the duration of the study;
- Written informed consent from parent or legal guardian;
- Participant and family have the ability to comply with the protocol requirements, in the opinion of the investigator.
Exclusion
- Non-English speaking parents;
- Psychosis;
- Taking clobazam, mTOR inhibitors (e.g sirolimus, tacrolimus), anti-cancer agents, citalopram \>20mg/day, escitalopram \>10mg/day.;
- Abnormal liver function tests: defined as ALT \> twice ULN;
- Abnormal renal function tests: defined as creatinine \> ULN
- Current use of medicinal cannabis, or use in the 4 weeks prior to screening;
- Pregnant or intending to become pregnant during the study, or breastfeeding;
- Known allergy to cannabidiol or cannabis products
Key Trial Info
Start Date :
May 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 19 2025
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT04821856
Start Date
May 11 2021
End Date
August 19 2025
Last Update
September 3 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
The Children's Hospital at Westmead
Westmead, New South Wales, Australia, 2145
2
Monash Children's Hospital
Clayton, Victoria, Australia, 3168
3
Royal Children's Hospital / Murdoch Children's Research Institute
Parkville, Victoria, Australia, 3052